Skip to main content
Profile picture for Jack Cush, MD

Jack Cush, MD

Dr. Cush is the Executive Editor of RheumNow.com and also Co-Edits the online textbook RheumaKnowledgy.com. 
  
Dr. Cush's interests include medical education, novel drug development, rheumatoid arthritis, spondyloarthritis, drug safety, and Still's disease/autoinflammatory syndromes. He has published over 140 articles and 2 books in rheumatology.
 
He can be followed on twitter: @RheumNow

Articles By Jack Cush, MD

lupus.bandtest.jpg

Best of 2018: Ustekinumab May be Effective in Lupus

Ronald F van Vollenhoven and colleagues have reported in Lancet that ustekinumab (UST), an interleukin-12 and -23 inhibitor, when added to usual therapy in systemic lupus erythematosus (SLE) patients, was shown to be superior to placebo at improving clinical efficacy and laboratory param

Read Article
knee.injx_.ant_.jpg

Best of 2018: Unproven But Profitable Stem Cell Clinics

Stem cell clinics are popular and proliferating as they are largely a cash business and fall outside of FDA regulatory control. In lieu of scientific proof, most advocates use patient testimonials and the placebo effect to back up their claims.

Read Article
katz-bw-square.jpg

Mourning the Loss of NIAMS Director Stephen Katz, MD, PhD

The following tribute to the late Dr. Steven Katz appeared on the NIH website. 

Read Article
WIR.large_.jpg (keep)

RheumNow Podcast – Rheumatologist Salaries (12.21.18)

Dr. Jack Cush reviews the news from RheumNow for the week ending 12/21/18.

Read Article
hip.fx2_.jpg

Zolendronate Protects Against Fracture in Osteopenia

The NEJM reports that the use of zoledronate significantly reduces the risk of nonvertebral or vertebral fragility fractures in women with osteopenia.

Read Article
Nailfold-capilaroscopy.jpg

Nailfold Videocapillaroscopy in Dermatomyositis

A study of nailfold videocapillaroscopy (NVC) in patients with idiopathic inflammatory myopathies (IIMs) finds abnormalities in more than half of patients suggesting this could be a useful clinical tool in diagnosing and managing patients with IIM. 

Read Article
pso.PsA_.NPF_.jpg

H2H: Ixekizumab vs. Adalimumab in Psoriatic Arthritis

Lilly has issued an advanced press release on its SPIRIT-H2H trial, wherein ixekizumab (Taltz) was shown to be more effective than than adalimumab (Humira) in a 24 week psoriatic arthritis study.

Read Article
medicare.jpg (keep)

Rising Physician Exclusion from Medicare and Medicaid

JAMA Network Open has published that an increasing number of physicians are being excluded from Medicare and other forms of public insurance. 

Read Article
RN.podcast.resized.jpg

RheumNow Podcast – Vasculitis and Strange Bedfellows (12.14.18)

Dr. Jack Cush reviews the news from the past week on RheumNow.com. 

Read Article
×